Exploring the Potential Mechanism of Umbilical Cord Mesenchymal Stem Cell Therapy for Chronic Atrophic Gastritis Based on Multi‐Omics Technology
Stem Cells International · 2026-01 · 2026 (1)
DOI: 10.1155/sci/3092047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells International, online erschienen am 13.03.2026. Verfasst von Pengchao Bai und 8 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Province Medical Science Research Key Project.
Abstract (Originalsprache)
Background
Chronic atrophic gastritis (CAG), a prevalent gastrointestinal disorder, is characterized by gastric mucosal atrophy and increased cancer risk. Mesenchymal stem cells (MSCs) exhibit immunomodulatory, anti‐inflammatory, and tissue‐regenerative properties; however, their therapeutic potential for CAG remains underexplored.
Methods
A rat CAG model was established using a multifactor induction protocol. Animals received weekly intravenous administrations of MSCs or MSC‐conditioned medium (MSC‐CM) for 4 weeks. Post‐treatment, gastric antral tissues were subjected to histopathological analysis, cytokine microarray, transcriptomics, proteomics, untargeted metabolomics, and lipidomics. Subsequently, the expression of CXCL9, CXCL10, and CXCL11 in the rat gastric antrum was verified by qPCR, and the expression of CDK1 protein was verified by Western blotting. In vitro validation was performed in IFN‐γ‐stimulated THP‐1 macrophages treated with MSC‐CM.
Results
At 20 weeks post‐modeling, significant mucosal atrophy was observed in the rat gastric antrum. H&E staining confirmed that both MSC and MSC‐CM treatments ameliorated histopathological atrophy. Cytokine microarray revealed downregulation of nine inflammatory mediators: G‐CSF, GM‐CSF, IFN‐γ, IL‐6, IL‐10, IL‐13, IL‐17α, M‐CSF, and MCP‐1. Multi‐omics and experimental data demonstrated aberrant upregulation of Cxcl9 / Cxcl10 / Cxcl11 , Cdk1, and D‐ribose in the CAG group, all significantly suppressed by MSC and MSC‐CM therapy. In THP‐1 cells, MSC‐CM dose‐dependently reduced CXCL9/CXCL10/CXCL11 and IL-6 expression.
Conclusions
MSCs likely exert their therapeutic efficacy against CAG primarily through paracrine mechanisms. Mechanistically, MSCs coordinately target the “CXCL9/CXCL10/CXCL11‐CDK1‐D‐ribose” axis to suppress inflammation and restore gastric mucosal atrophy.
Förderung
- Hebei Province Medical Science Research Key Project
Zitieren
APA
Bai, P., Liu, Q., Yin, M., Liu, Y., Sui, J., Wang, S., Jia, R., Liu, H., & Zhao, F. (2026). Exploring the Potential Mechanism of Umbilical Cord Mesenchymal Stem Cell Therapy for Chronic Atrophic Gastritis Based on Multi‐Omics Technology. Stem Cells International, 2026(1). https://doi.org/10.1155/sci/3092047
Vancouver
Bai P, Liu Q, Yin M, Liu Y, Sui J, Wang S, et al. Exploring the Potential Mechanism of Umbilical Cord Mesenchymal Stem Cell Therapy for Chronic Atrophic Gastritis Based on Multi‐Omics Technology. Stem Cells International. 2026;2026(1). doi:10.1155/sci/3092047
BibTeX
@article{Bai2026,
author = {Bai, Pengchao and Liu, Qichao and Yin, Miaomiao and Liu, Yan and Sui, Jianliang and Wang, Saihan and Jia, Ruikang and Liu, Huiyun and Zhao, Feiyue},
title = {Exploring the Potential Mechanism of Umbilical Cord Mesenchymal Stem Cell Therapy for Chronic Atrophic Gastritis Based on Multi‐Omics Technology},
journal = {Stem Cells International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/sci/3092047}
}
EUVIMED